Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare Study

总结 结直肠癌（CRC）是美国男性和女性中第二常见的癌症，导致 每年有超过五万人死亡研究旨在减少CRC的高负担，发现/验证新的 与预后相关的生物标志物，解决早发性CRC日益增长的流行病， 服务不足人群中的CRC差异至关重要。CRC患者队列，包括不同的 人口和纵向确定临床数据和生物标本是必不可少的追求这些关键 目标. ColoCare研究是一项大型的多机构前瞻性生存队列研究， 来自不同种族/民族和地理背景的确诊CRC患者。CRC生存率 队列是罕见的，ColoCare是独一无二的，因为它收集了详细的流行病学和临床数据， 多个时间点的各种生物标本。这种设计使创新的生存研究， 跨越生活方式/行为因素，种族/民族CRC差异，以及旨在发现 以及验证与不良CRC风险相关的新型分子、血液和微生物生物标志物 成果。这些研究可以为治疗决策提供信息，旨在改善关键临床症状的干预措施， 和患者报告的结果，以及新疗法的发展。 ColoCare研究招募了超过3，000名患者，中位随访时间为2.1年， 收集包括肿瘤组织和系列血液、粪便和尿液样本。尽管是一个年轻的群体， ColoCare已经支持了70篇已发表的论文和79个项目，其中包括72名外部研究人员。 持续的U01基础设施支持对于维持和发展CRC生存的这一宝贵资源至关重要 research.在这方面，我们会致力达致以下目的：（1）把学生人数由3，361人增至4，157人 参与者，包括加强征聘服务不足和研究不足的人口， CRC结果的显著差异，以及接受新疗法的患者。(2)延长参与者随访 通过主动随访（生物标本;问卷;病历摘要）和 被动随访（SEER/州癌症登记处和国家死亡指数）。(3)维持和扩大 ColoCare生物储存库，包括收集肿瘤组织样本和纵向收集血液和 粪便样本(4)维护和扩展ColoCare中央数据仓库，我们的研究能力 门户网站，以鼓励和促进外部和内部调查人员的请求，并与我们的 社区咨询委员会推动患者参与和公众知识传播 由ColoCare生成。在持续的基础设施支持下，这一独特而全面的资源将 继续开展广泛的有影响力的结直肠癌生存率研究。

SUMMARY Colorectal cancer (CRC) is the second most common cancer among men and women in the U.S., leading to over 50,000 deaths per year. Research aimed at reducing CRC’s high burden, discovering/validating novel biomarkers associated with prognosis, addressing the growing epidemic of early-onset CRC, and countering CRC disparities in underserved populations is of pressing importance. CRC patient cohorts that include diverse populations and longitudinally ascertain clinical data and biospecimens are essential for pursuing these critical objectives. The ColoCare Study is a large, multi-institutional prospective survivorship cohort that enrolls newly diagnosed patients with CRC from diverse racial/ethnic and geographic backgrounds. CRC survivorship cohorts are rare and ColoCare is unique given its collection of detailed epidemiologic and clinical data and a variety of biospecimens at multiple time points. This design enables innovative survivorship research that spans lifestyle/behavioral factors, racial/ethnic CRC disparities, and translational studies aimed at discovering and validating novel molecular, blood- and microbiome-based biomarkers related to the risk of adverse CRC outcomes. Such research can inform treatment decision-making, interventions aimed at improving key clinical and patient reported outcomes, and the development of novel therapeutics. The ColoCare Study has enrolled >3,000 patients with a median of 2.1 years of follow-up and biospecimen collections including tumor tissue and serial blood, stool, and urine samples. Despite being a young cohort, ColoCare has already supported 70 published papers and 79 projects that include 72 external investigators. Continued U01 infrastructure support is critical to sustain and grow this valuable resource for CRC survivorship research. Here, we will pursue the following aims: (1) Increase the size of the cohort from 3,361 to 4,157 participants, including enhanced recruitment of underserved and understudied populations who experience significant disparities in CRC outcomes, and patients receiving novel therapies. (2) Extend participant follow-up to 5-years through both active follow-up (biospecimens; questionnaires; medical record abstractions) and passive follow-up (SEER/state cancer registries and National Death Index). (3) Maintain and expand the ColoCare biorepository, including collection of tumor tissue samples and longitudinal collections of blood and stool samples. (4) Maintain and expand the ColoCare Central Data Warehouse, the capabilities of our study portal to encourage and facilitate requests from external and internal investigators, and engagement with our Community Advisory Board to advance patient participation and the public dissemination of knowledge generated by ColoCare. With continued infrastructure support, this unique and comprehensive resource will continue to enable a wide-range of impactful colorectal cancer survivorship research.